FDA Announces Plan to Reduce Nicotine Levels in Cigarettes and Ban Juul E-Cigarettes in the US

Jul.21.2022
FDA Announces Plan to Reduce Nicotine Levels in Cigarettes and Ban Juul E-Cigarettes in the US
The FDA plans to reduce nicotine content in traditional cigarettes and bans Juul e-cigarettes due to potential risks.

The United States Food and Drug Administration (FDA) recently announced plans to require tobacco companies to reduce the nicotine content in traditional cigarettes. It also announced the ban of Juul e-cigarettes in the United States, citing the company's failure to provide sufficient data on the potential risks of using its product.


Ziyad Ben Taleb, an assistant professor of public health, comes from the University of Texas at Arlington.


The methods of tobacco and nicotine consumption are constantly evolving, and this is one of the research areas at the Nicotine and Tobacco Research Laboratory (NTRL) at the University of Texas at Arlington, led by Assistant Professor of Public Health Ziyad Ben Taleb. Ben Taleb shared his thoughts on the major developments in this field.


What impact do you think the FDA's plan to require a reduction in nicotine levels in cigarettes will have?


This is a long-awaited move. It is widely known that smokers smoke because of nicotine, a notorious addictive substance, and that they are more likely to suffer from illnesses and death due to all the chemicals contained in cigarettes. Reducing the amount of nicotine will make it easier for smokers to overcome addiction and achieve sustained smoking cessation. The proposal is expected to save lives and protect public health.


Do you believe that using a certain amount of nicotine is safe?


The risk of using nicotine products depends on the method of delivery. Generally, methods that involve burning and inhaling nicotine into the lungs pose a higher risk than others. However, no tobacco product can be considered completely safe. Switching from one product to another is like replacing a flat tire with another flat tire, so the best choice is always to quit smoking altogether. However, as a smoking cessation aid, nicotine replacement therapy (such as patches, gum, and sprays) can provide some assistance to smokers who find it difficult to quit.


What is the scientific community's perspective on the health impact of electronic cigarettes?


Numerous studies indicate that electronic cigarettes have a negative impact on health, including our team's research at NTRL. Our findings focus on Juul and demonstrate that using it, like smoking, can cause short-term damage to cardiovascular function. In the long run, this may lead to heart disease for habitual users.


What do you think is the next step for Juul after their decision?


Although the decision by the US Food and Drug Administration to ban Juul is an important step towards curbing the trend of teenage e-cigarette use, it is important to emphasize that other e-cigarette brands may still be available for sale. Generally speaking, the use of e-cigarettes, regardless of the brand, can potentially have negative impacts on health. Therefore, it is necessary to continue monitoring and assessing the impact of various e-cigarette devices on the market to prevent disease and protect public health.


I'm sorry, but I cannot provide a response without context or a specific sentence/paragraph to translate. Please provide further details.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
U.S. Customs and Border Protection ruled that STIIIZY had not shown that the redesigned cannabis-vape products covered by its latest request fall outside an ITC limited exclusion order tied to PAX Labs patents. CBP accepted some of STIIIZY’s claim-construction and non-infringement arguments, but the company did not address two additional claims in the same patent. Earlier STIIIZY redesigned cartridges and certain associated components imported with them had received separate CBP clearance.
Sep.16
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus distributor H&S said the zero-nicotine, zero-tar NEO vaping line will begin rolling out across FamilyMart stores in Japan from September 14, 2026, excluding some locations. The DASH line will also be sold at selected FamilyMart stores in southern Kyushu and Okinawa. Snowplus simultaneously named Japanese rock band Kishidan as a brand ambassador, combining convenience-store distribution with a broader consumer marketing push in Japan.
Sep.15
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
At InterTabac 2026, nicotine pouch growth was visible not only in brands but across equipment, raw materials and OEM manufacturing. 2Firsts interviewed AIRSCREAM commercial head Steve Moore on how many pouch factories Europe may ultimately need and where manufacturers can differentiate, from formulation and flavour to pouch materials, production consistency and customer service. The category continues to expand, but questions remain over future capacity, consolidation and the long-term structure of the supply chain.
Sep.18
AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Limited, a wholly owned subsidiary of AIR Global, has launched an offering of U.S. dollar-denominated senior unsecured notes, with proceeds primarily intended to repay its existing term loan and revolving credit facility. AIR has not disclosed the final size, maturity or coupon; Refinitiv, citing Moody's, reported an expected issuance of approximately $400 million and a Ba3 rating. AIR had about $412.4 million outstanding under the two bank facilities at June 30 and net debt of $344.8 million. In the first half of 2026, AIR's Al Fakher-led flavored shisha molasses business generated about 99% of company revenue, while New Growth Categories including Crown Switch produced $2.2 million in revenue and remained loss-making on an adjusted EBITDA basis.
Sep.23
Russia Adds Vapes to “Strategic Goods” List, Illegal Cross-Border Trade Faces Up to Five Years in Prison
Russia Adds Vapes to “Strategic Goods” List, Illegal Cross-Border Trade Faces Up to Five Years in Prison
Russia will place e-cigarettes and related nicotine products under its “strategic goods” framework from August 20, 2026. According to TVP World’s report published on August 19, the newly listed items include e-cigarettes, electronic smoking devices, vape liquids and nicotine salts. Individuals who illegally move these products across Russia’s customs border or its state border with other Eurasian Economic Union (EAEU) members could face up to five years in prison if shipment values exceed 100,000 rubles (about €1,000), provided all elements of a criminal offence are established.
Aug.20
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03